GLP-1 medications and the gut lining: what the evidence actually shows
No human study shows these medications harming the intestinal barrier, and the early evidence points the other way. Here is what is known, what isn't, and where glutamine fits.
Do GLP-1 medications damage the gut lining?
No human study shows that they do. Research on GLP-1 receptor agonists and the intestinal barrier is mostly preclinical, and in animal models of colitis these drugs preserved barrier integrity rather than harming it [1]. The first human randomized trial in this area was designed to test whether semaglutide improves intestinal permeability, not whether it worsens it [2].
Key numbers
- No human study shows GLP-1 medications damaging the intestinal barrier [1].
- In animal models of colitis, GLP-1 receptor agonists preserved the gut barrier rather than harming it, and the first human trial was designed to test whether semaglutide improves intestinal permeability [1, 2].
- The human gut lining renews on average every 3.5 days, from a meta-analysis of 85 studies [3].
- The strongest glutamine trial used 15 g a day in people with post-infectious IBS and measured hyperpermeability; a 2024 meta-analysis found effects on permeability only at 30 g a day or more [4, 5].
What is actually known about GLP-1 drugs and the intestinal barrier?
Less than supplement marketing suggests. Most evidence is from animals or from observational human studies of gut bacteria, and early work in inflammatory bowel disease suggests GLP-1 receptor agonists may be protective rather than harmful [1]. A randomized trial comparing semaglutide with placebo was set up to measure intestinal permeability directly, and we found no published results [2].
- What the animal work shows
- In colitis models, GLP-1 receptor agonists were associated with preserved epithelial integrity and less inflammation [1].
- What the human work shows
- Mostly observational data on gut bacteria, plus retrospective studies in inflammatory bowel disease suggesting better outcomes for patients taking these drugs [1].
- What is being tested now
- A randomized trial of semaglutide versus placebo in adults with type 2 diabetes, built specifically to measure intestinal permeability, with the stated hypothesis that semaglutide improves it [2].
- What nobody has shown
- No human study we could find reports GLP-1 medications damaging, thinning or weakening the intestinal barrier in people.
How fast does the gut lining renew itself?
About every three and a half days, on average. A meta-analysis of 85 studies covering 1,602 subjects across six species found human gastrointestinal epithelial turnover of 3.48 days, slower than mice at 2.81 days or rats at 2.37 days [3]. That average comes with a wide spread, so treat it as a rough rate rather than a schedule.
Those cells are energy-hungry. In isolated human intestinal cells, glutamine, glutamate and glucose were the only substrates that produced major increases in oxygen consumption, with glutamine used at about 14.9 micromol per minute per gram of dry weight [6]. Reviews describe glutamine as a preferred fuel for these cells, though whether it is uniquely so has been debated for decades [7].
Does eating much less affect the gut lining?
Nobody has measured that in people taking GLP-1 medications. What is documented is that intake drops sharply on these drugs, by 16% to 39% compared with placebo [8], and that protein intake often falls short: only 43% of GLP-1 users in one food-record study reached 1.2 g per kilogram [9]. Whether that changes the intestinal barrier in this population is untested.
That is the honest state of it: a plausible mechanism, no measurements. If you want to act on something with evidence behind it, protein intake is the better target, because the advisory sets targets for it and links low intake to muscle loss [8]. See our guide to protein on a GLP-1 medication.
Does L-glutamine help the gut lining?
In one specific group, yes; beyond that group, the evidence thins fast. In a randomized trial, adults with post-infectious diarrhoea-predominant IBS who had measured hyperpermeability took 5 g of glutamine three times a day for 8 weeks: 79.6% met the primary symptom endpoint versus 5.8% on placebo, and permeability normalized in the glutamine group only [4].
- Who was studied
- Adults with post-infectious IBS-D and a lactulose/mannitol ratio of at least 0.07, meaning permeability was measured, not assumed. 54 glutamine and 52 placebo participants completed [4].
- Dose used
- 15 g a day, taken as 5 g three times daily for 8 weeks [4].
- What a meta-analysis found
- A 2024 review pooling trials of glutamine and gut permeability found a significant effect only in studies using 30 g a day or more, not in studies below that [5].
- Other populations
- A randomized trial in Crohn's disease reported improved permeability and intestinal morphology with glutamine plus whey protein [10].
- What it doesn't show
- Nothing here was tested in people taking GLP-1 medications, and none of these participants were healthy people taking glutamine as a general supplement.
So the honest summary is narrow: glutamine has real evidence in specific gut conditions at doses well above what most supplements provide, and no evidence at all in GLP-1 users.
Should you take glutamine while on a GLP-1?
There is no evidence either way for that specific question, so it is a conversation for your prescriber rather than a decision to make from a product page. If you are choosing where to put effort and money, protein intake and the nutrients with documented shortfalls on these medications have far more evidence behind them [8, 11].
For the nutrients that do show measured shortfalls, see our guide to nutrient deficiencies on GLP-1 medications.
Where Understory fits, and what we are not saying
Understory is finishing a second protocol in this area. That is exactly why this page is worth reading carefully: the usual pitch for products like it assumes these medications are damaging your digestive tract, and we could not find human evidence for that. We are not making that claim.
Until the second protocol's label is final we are not publishing its doses, its ingredients or any claim for it. When it launches, the label goes up and any claim we make will be traceable to a study listed on this site, alongside the studies that cut the other way.
Protocol One, which is available now, is a vitamin, mineral and digestive supplement designed to be taken alongside a GLP-1 medication. It is not a gut-lining product and we make no gut-lining claim for it. See what it actually contains.
What this evidence can't tell you
- Animal results don't transfer reliably to people, and most of the GLP-1 barrier work is in animals [1].
- The human trial designed to measure permeability on semaglutide had no results we could find, so the direct question remains open [2].
- The glutamine trials were in people with diagnosed gut conditions and measured hyperpermeability, at doses of 15 g a day or more [4, 5].
- The turnover figure is a meta-analysis mean with a wide spread, not a fixed timetable [3].
- If a study lands that changes any of this, including one that contradicts us, this page gets updated and the review date changes.
Sources
- Narrative review of GLP-1 receptor agonists, intestinal barrier function and the gut microbiome. Frontiers in Endocrinology. 2026. Full text. Narrative review; most underlying data are preclinical or observational.
- Rella S, et al. Effects of semaglutide on intestinal permeability in patients with type 2 diabetes (SIB): study design. Therapeutic Advances in Endocrinology and Metabolism. 2023. doi:10.1177/20420188231207348 PubMed. Design paper; the stated hypothesis is that semaglutide improves intestinal permeability. No results found as of September 2026.
- Darwich AS, Aslam U, Ashcroft DM, Rostami-Hodjegan A. Meta-analysis of the turnover of intestinal epithelia in preclinical animal species and humans. Drug Metabolism and Disposition. 2014;42(12):2016-2022. PubMed. 85 studies, 1,602 subjects, six species.
- Zhou Q, Verne ML, Fields JZ, et al. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut. 2019;68(6):996-1002. doi:10.1136/gutjnl-2017-315136 Full text. Participants had post-infectious IBS-D with measured intestinal hyperpermeability.
- Systematic review and meta-analysis of clinical trials on glutamine supplementation and intestinal permeability. Amino Acids. 2024. doi:10.1007/s00726-024-03420-7. Pooled effect on permeability was significant only in studies using 30 g/day or more.
- Glucose, glutamine, and ketone-body metabolism in human enterocytes. Metabolism. 1988. PubMed.
- Is glutamine a unique fuel for small intestinal cells? (review of the debate over glutamine's role as an enterocyte fuel). Record.
- Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory. Obesity. 2025;33(8):1475-1503. doi:10.1002/oby.24336 Full text.
- Johnson B, Milstead M, Thomas O, et al. Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study. Frontiers in Nutrition. 2025;12:1566498. doi:10.3389/fnut.2025.1566498. 69 adults; funded by GNC Holdings.
- Benjamin J, Makharia G, Ahuja V, et al. Glutamine and whey protein improve intestinal permeability and morphology in patients with Crohn's disease: a randomized controlled trial. Digestive Diseases and Sciences. 2012;57:1000-1012. doi:10.1007/s10620-011-1947-9.
- Butsch WS, Sulo S, Chang AT, et al. Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: a retrospective observational study. Obesity Pillars. 2025;15:100186. doi:10.1016/j.obpill.2025.100186. 461,382 adults; funded by Abbott.
These statements have not been evaluated by the Food and Drug Administration. Understory Nutrition products are not intended to diagnose, treat, cure, or prevent any disease. This page is general information, not medical advice. Talk with your prescriber before starting any supplement, especially alongside a prescription medication.